1. PTHrP promotes malignancy of human oral cancer cell downstream of the EGFR signaling
- Author
-
Hideaki Kawaguchi, Yasunori Totsuka, Masumi Tsuda, Yusuke Ohba, Masanobu Shindoh, and Tamaki Yamada
- Subjects
musculoskeletal diseases ,MAPK/ERK pathway ,medicine.medical_specialty ,PTHrP ,EGFR ,Biophysics ,Therapeutics ,Biochemistry ,Paracrine signalling ,RNA interference ,Internal medicine ,medicine ,Tumor Cells, Cultured ,Humans ,Epidermal growth factor receptor ,Autocrine signalling ,Molecular Biology ,EGFR inhibitors ,Cell Proliferation ,Gene knockdown ,biology ,Cell growth ,Oral cancer ,Parathyroid Hormone-Related Protein ,Cell Biology ,musculoskeletal system ,ErbB Receptors ,Endocrinology ,AG1478 ,Cancer cell ,Cancer research ,biology.protein ,Carcinoma, Squamous Cell ,Mouth Neoplasms ,hormones, hormone substitutes, and hormone antagonists ,Signal Transduction - Abstract
Parathyroid hormone-related protein (PTHrP) is detected in many aggressive tumors and involved in malignant conversion; however, the underlying mechanism remains obscure. Here, we identified PTHrP as a mediator of epidermal growth factor receptor (EGFR) signaling to promote the malignancies of oral cancers. PTHrP mRNA was abundantly expressed in most of the quiescent oral cancer cells, and was significantly upregulated by EGF stimulation via ERK and p38 MAPK. PTHrP silencing by RNA interference, as well as EGFR inhibitor AG1478 treatment, significantly suppressed cell proliferation, migration, and invasiveness. Furthermore, combined treatment of AG1478 and PTHrP knockdown achieved synergistic inhibition of malignant phenotypes. Recombinant PTHrP substantially promoted cell motility, and rescued the inhibition by PTHrP knockdown, suggesting the paracrine/autocrine function of PTHrP. These data indicate that PTHrP contributes to the malignancy of oral cancers downstream of EGFR signaling, and may thus provide a therapeutic target for oral cancer.
- Published
- 2008